Ind-swift Laboratories Ltd. · NSE:INDSWFTLAB
Ind-swift Laboratories — Q2 FY21 Earnings Presentation
28 slides from Ind-swift Laboratories's earnings presentation, Nov 18, 2020
Slide 1: Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited (A Recognised Export House) Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101 Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com CIN No. L24232CH1995PL
Slide 2: Investor Presentation Q2 & H1FY21
Ind-Swift Laboratories Limited Investor Presentation Q2 & H1FY21 1
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Ind-Swift Laboratories Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Contents
Contents Q2 & H1FY21 Performance & 01 Highlights Company 02 Overview Industry Outlook & 03 Growth Strategy Historical 04 Financials 3
Slide 5: Q2 & H1FY21 Performance & Highlights
Q2 & H1FY21 Performance & Highlights
Slide 6: Standalone Financial highlights – Q2FY21
Standalone Financial highlights – Q2FY21 Rs cr Revenue EBITDA 13.3% 31.7% 200 227 41 54 Q2FY20 Q2FY21 Q2FY20 Q2FY21 PAT Cash Profit 141.1% -11 9 12 29 Q2FY20 Q2FY21 Q2FY20 Q2FY21 5
Slide 7: Standalone Financial highlights – H1FY21
Standalone Financial highlights – H1FY21 Rs cr Revenue EBITDA 12.8% 22.6% 387 437 84 103 H1FY20 H1FY21 H1FY20 H1FY21 PAT Cash Profit 102.4% -19 13 26 53 H1FY20 H1FY21 H1FY20 H1FY21 6
Slide 8: Operating revenue breakup – healthy export growth
Operating revenue breakup – healthy export growth Rs cr Domestic Export 59 53 162 137 Q2FY20 Q2FY21 Q2FY20 Q2FY21 Domestic Export 113 312 104 266 H1FY20 H1FY21 H1FY20 H1FY21 7
Slide 9: Standalone Profit & Loss Statement
Standalone Profit & Loss Statement (Rs Cr) Q2FY21 Q2FY20 YoY H1FY21 H1FY20 YoY Revenue from Operations 221 190 425 371 Other Income 6 11 12 16 Total Income 227 200 13.3% 437 387 12.8% Cost of Raw Material 101 102 207 192 Gross Profit 126 98 28.1% 230 196 17.3% Gross Profit margin 55.3% 48.9% 52.5% 5
Slide 10: Standalone Balance Sheet
Standalone Balance Sheet (Rs. Cr) Sep-20 Mar-20 (Rs. Cr) Sep-20 Mar-20 EQUITY & LIABILITY ASSETS Share Capital 60 60 Non-Current Assets Total Reserves 598 585 Fixed Assets incl CWIP & intangible 819 854 Shareholder's Funds 658 645 Investment in subsidiary 26 26 Long-Term Borrowings Financial Assets
Slide 11: Company Overview
Company Overview
Slide 12: A leading API player
A leading API player 788 cr 22.6% 280+ 7-8 years 70+ Revenue EBITDA Margin Customers Retention period for Countries with FY20 FY20 top 10 customers product presence 32 18 2500+ 690 KL 696 MT Molecules Therapeutic Employees Reactor capacity Bulk drug capacity Categories R&D Infrastructure With Strong
Slide 13: Corporate History
Corporate History 2005 2007 2011 Second Plant at Jammu USFDA site USFDA site 2015 2018 established approval (total DMF approval filed: 9) (total DMF 1995 1998 filed: 20) USFDA site USFDA site Incorporated First Plant at by Ind Swift Derabassi 2006 approval approval 2010 Limited with commences $10m G
Slide 14: Key Products
Broad portfolio across multiple therapeutic areas FY20 Standalone Number of Product Indication Revenue FY20 Revenue Share Clients (Rs Cr) Clarithromycin Anti-infective 155 239 Fexofenadine Allergic rhinitis 62 114 22% Atorvastatin Hypercholesterolaemia 85 103 32% Clopidogrel Atherothrombotic events
Slide 15: Geographical Revenue Breakup
.. With significant market share in key products Global Market Share by Volume FY20 8% Clarithromycin 25% Geographical Revenue Breakup Fexofenadine 20-25% 30% 19% Atorvastatin 10% Key Products Clopidogrel 15-18% Ezetimibe 8% Nitazoxanide 40% 15% 19% Ivabradine 25% 9% Not depicted in the chart above
Slide 16: Key Highlights: Growing CRAMS opportunities
Growing CRAMS opportunities ▪ Involved in pharmaceutical CRAMS applications for several years and recently ventured into CRAMS for specialty chemicals in the display technology space ▪ Plans to capitalize on reducing dependency on China for supply of such intermediates ▪ Key features of CRAMS for th
Slide 17: Derabassi Facility
High quality manufacturing facilities Reaction Capacity: 510KL Over 33 acres 22 cGMP plants Zero discharge Derabassi Facility ▪ GMP pilot plant suitable for Advanced Intermediates, key starting material required for manufacturing API. ▪ Dedicated facility for Oncology products with world-class Isola
Slide 18: Mohali R&D Overview
Dedicated R&D infrastructure with strong capabilities 11 products in pipeline with 4 Mohali R&D Center included to commercialize by FY22 474 DMFs 119 scientists Mohali R&D Overview • State-of-the-art R&D campus over 2 acres • 147 highly qualified R&D employees including 119 scientists, approved by D
Slide 19: Long standing relationship with key customers
Long standing relationship with key customers Proudly maintaining long standing relationships with multiple clients for 10+ years 18
Slide 20: Represented by a professional team
Represented by a professional team Mr. Nav Rattan Munjal Dr. Lalit Wadhwa Mr. Vijay Kumar Chairman & Managing Director Chief Operating Officer Director of Marketing • Responsible for overall corporate strategy • Responsible for overall operations • Responsible for marketing operations (except • Scie
Slide 21: Industry Outlook & Growth Strategy
Industry Outlook & Growth Strategy
Slide 22: Large, attractive and growing API market
Large, attractive and growing API market Worldwide Generic Drug Sales ($Bn) As branded drugs become off-patent, exports CAGR – 6.1% of generics to US will rise 101 106 90 95 79 84 Affordability of drugs will rise due to sustained growth in incomes and in insurance coverage Population growth at aroun
Slide 23: With government led initiatives
With government led initiatives Reducing Dependency on China • China is the leader in API manufacturing with over 70% of raw materials for global API production being imported from China • With India’s increasing cost competitiveness the Govt. plans to reduce import dependency on China by encouragin
Slide 24: Growth strategy to tap into opportunities
Growth strategy to tap into opportunities 1 2 Existing and New Product Pipeline New Markets ▪ Stable revenue stream on the back of deep ▪ Increase revenue share from higher margin relationship with long lasting customers regulated markets ▪ Continued growth in volume ▪ Strengthening marketing teams
Slide 25: Historical Financials
Historical Financials
Slide 26: Standalone financial highlights
Standalone financial highlights Revenue (Rs Cr) EBITDA & EBITDA Margin (Rs Cr) 750 771 788 19.4% 22.3% 22.6% 172 178 145 FY18 FY19 FY20 FY18 FY19 FY20 PBT (Rs Cr) 59 29 -20 FY18 FY19 FY20 ✓ Exceptional income of 83 crores in FY19 on account of one time settlement with banks and financial institution
Slide 27: Standalone Profit & Loss Statement
Standalone Profit & Loss Statement Rs Cr FY20 FY19 FY18 Revenue from Operations 752 724 731 Other Income 36 47 18 Total Income 788 771 750 Cost of Raw Material 379 379 375 Gross Profit 409 392 375 Gross Profit margin 51.9% 50.8% 50.0% Employee Benefit Expense 100 95 89 Other Expenses 131 124 140 Tot
Slide 28: Thank You
Thank You Ind-Swift Laboratories Limited Gagan Aggarwal - CFO gagan@indswiftlabs.com Pardeep Verma – AVP – Corporate Affairs and Company Secretary pardeep.verma@indswiftlabs.com Pareto Capital (Investor Relations) Pooja Dokania pooja.dokania@paretocapital.in Rishav Das rishav.das@paretocapital.in
Ind-Swift Laboratories — Q2 FY21 Earnings Presentation on 6ix